🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

IL-21 engineering enhances NK cell activity against glioblastoma via CEBPD Cancer Cell cell.com/cancer-cell/fu… Nicholas Huntington cell.com/cancer-cell/fu… Katy Rezvani, M.D., Ph.D Mayra Shanley

Our CSO Nicholas Huntington penned an expert preview for 𝘊𝘢𝘯𝘤𝘦𝘳 𝘊𝘦𝘭𝘭 summarizing the significance of a recent Katy Rezvani, M.D., Ph.D study creating 'armored' natural killer cell therapies for #glioblastoma & the power of IL-21: sciencedirect.com/science/articl… #Cancer #Immunotherapy #nkcells

Another PhD thesis submitted from Huntington Lab Monash Biomedicine Discovery Institute Congrats Harrison Sudholz on a high quality 3 years of NK cell discoveries. C'arn the Hawks!!!

Congrats Harrison Sudholz on the PhD thesis defence. Was a ripping defence, reminded me of Brandon Starcevich in the Grand Final 🦁

Looking forward to connecting with all my cancer immunology colleagues for Society for Immunotherapy of Cancer in Houston in 2 weeks!

Lewis finally got that Grand Ballroom named after him #SITC2024 🤩

#SITC2024 hangs with Dr Becs & A/Prof Paul Beavis who gave a brilliant talk on novel strategies to improve CAR T cell function in solid tumors

NK cell sesh #STIC2024 Genome-wide CRISPR screens in NK cells discovers the IL-15R regulome, >10 ph I NK cell therapy trials & aNKG2A mAb in Ph III. We've come a long way in 5 years Katy Rezvani, M.D., Ph.D Eric Vivier oNKo-innate Innate Pharma MD Anderson Cancer Center

Our CSO, Nicholas Huntington shares his expert perspective on a recent Nature publication involving IL-15 armored CAR-T cell therapy... 🧵1/7 nature.com/articles/s4158… #immunooncology #CARTcelltherapy #interleukin15 #cancer #cancerresearch

NK cells are not T cells. How we target them in immunotherapy strategies must respect this. Some fresh thoughts on this from our team 👇

🧵13/ In summary, we identify🔎CREM as a key🔑transcriptional checkpoint that limits CAR-NK cell function and persistence. Induced by CAR/CD3ζ ITAM and IL-15 signaling via the PKA–CREB axis, CREM promotes an exhaustion-like state. CREM KO enhances cytotoxicity, cytokine

Researchers including Dr. Nicholas Huntington (Nicholas Huntington) at Monash Biomedicine Discovery Institute reveal the complete IL-15R signaling mechanism in NK cells and discover that ubiquitin-dependent IL-15R degradation is the dominant mechanism restraining IL-15R signaling. 💡 bit.ly/3TphMxE

Congrats A/Prof Paul Beavis et al. Huge biology and underscores the key role of IL-12 in solid tumor immunity and validates our oNKo-innate oNKo-044 IL-12 biologic. These approaches should be prioritised by Biopharma looking to get a signal with cell therapies in solid tumors